AstraZeneca Pharma India · NSE: ASTRAZEN · BSE: 506820
Q1 FY21 results · Apr–Jun 2020
AstraZeneca Pharma India reported revenue from operations of ₹1,935.78 crore (up 846.3% from Q1 FY20) and net profit of ₹186.35 crore (up 766.1% from Q1 FY20) for Q1 FY21 (Apr–Jun 2020), on a standalone basis.
| Item | Q1 FY21 | Q1 FY20 | YoY | Q4 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,935.78 | 204.56 | +846.3% | 194.90 | +893.2% |
| Other income | 26.48 | 2.99 | +785.9% | 3.38 | +684.3% |
| Total income | 1,962.26 | 207.55 | +845.4% | 198.28 | +889.6% |
| Profit before tax | 263.84 | 33.63 | +684.6% | 13.35 | 20x |
| Net profit for the period | 186.35 | 21.52 | +766.1% | 9.58 | 19x |
| EPS, basic (₹) | 7.45 | 8.61 | not comparable | 3.83 | not comparable |
| Net margin (%) | 9.6 | 10.5 | 4.9 |
Standalone
- Filed with BSE
- 11 Aug 2020, 13:32 IST
- Board meeting
- 10 Aug 2020
- Period
- 01 Apr 2020 to 30 Jun 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE